Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study
Academic Article
Publication Date:
2022
Short description:
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study / Visentin, A., Mauro, F.R., Cibien, F., Vitale, C., Reda, G., Fresa, A., Ciolli, S., Pietrasanta, D., Marchetti, M., Murru, R., Gentile, M., Rigolin, G.M., Quaglia, F.M., Scarfo', L., Sportoletti, P., Pravato, S., Piazza, F., Coscia, M., Laurenti, L., Molica, S., et al.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 97:3(2022), pp. E95-E99. [10.1002/ajh.26437]
Iris type:
1.1 Articolo in rivista
List of contributors:
Visentin, A.; Mauro, F. R.; Cibien, F.; Vitale, C.; Reda, G.; Fresa, A.; Ciolli, S.; Pietrasanta, D.; Marchetti, M.; Murru, R.; Gentile, M.; Rigolin, G. M.; Quaglia, F. M.; Scarfo', L.; Sportoletti, P.; Pravato, S.; Piazza, F.; Coscia, M.; Laurenti, L.; Molica, S.; Foa, R.; Cuneo, A.; Trentin, L.
Published in: